GelStat Corp. (GSAC)
0.0004
0.00 (0.00%)
USD |
OTCM |
Dec 12, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.0446M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -12.50% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.912 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.68% |
Profile
| GelStat Corp. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes GelStat Migraine, Chews 2 Lose, All Natural Speed, and GelStat Speed. The company was founded on November 13, 1991 and is headquartered in Miami, FL. |
| URL | http://www.gelstat.com |
| Investor Relations URL | N/A |
| HQ State/Province | Florida |
| Sector | |
| Industry | |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| GelStat Corp. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes GelStat Migraine, Chews 2 Lose, All Natural Speed, and GelStat Speed. The company was founded on November 13, 1991 and is headquartered in Miami, FL. |
| URL | http://www.gelstat.com |
| Investor Relations URL | N/A |
| HQ State/Province | Florida |
| Sector | |
| Industry | |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |